Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NRT 6003

Next Previous
Drug Profile

NRT 6003

Alternative Names: NRT-6003; Yttrium-90 [90Y]; Yttrium-90 carbon microspheres

Latest Information Update: 25 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chengdu New Radiomedicine Technology
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liver cancer
  • Preclinical Pancreatic cancer

Most Recent Events

  • 18 Jun 2026 Second Affiliated Hospital of Guangzhou Medical University plans phase II trial in Liver cancer (Second-line therapy and greater) in China (IV) (NCT07657273)
  • 29 May 2026 Efficacy, adverse evenet and pharmacodynamics data from a phase I trial in Liver cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology 2026 (ASCO-2026)
  • 10 Jun 2025 Chengdu New Radiomedicine Technology completes the phase I trial in Liver cancer (Inoperable/Unresectable) in China (IV, Injection) (NCT06310590)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top